Dataset from An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications

The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous \[IV\]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously \[SC\]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed CD stratified at higher risk for complications.

本研究旨在明确三联联合疗法对新诊断为克罗恩病（CD, Crohn's Disease）且被分层为并发症高风险的受试者的内镜缓解疗效，该三联疗法包含抗整合素（anti-integrin）类药物维得利珠单抗静脉输注（IV）、肿瘤坏死因子（TNF）拮抗剂阿达木单抗皮下注射（SC）以及免疫调节剂口服甲氨蝶呤。